Cargando…

Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis

BACKGROUND: There is robust evidence that schizophrenia is characterized by immune-inflammatory abnormalities, including variations on cytokine levels. The results of previous studies, however, are heterogeneous due to several confounding factors, such as the effects of antipsychotic drugs. Therefor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noto, Cristiano, Ota, Vanessa Kiyomi, Gouvea, Eduardo S., Rizzo, Lucas B., Spindola, Leticia M. N., Honda, Pedro H. S., Cordeiro, Quirino, Belangero, Sintia Iole, Bressan, Rodrigo Affonseca, Gadelha, Ary, Maes, Michael, Brietzke, Elisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4360233/ https://www.ncbi.nlm.nih.gov/pubmed/25522386 http://dx.doi.org/10.1093/ijnp/pyu042

Ejemplares similares

O8.2. DURATION OF UNTREATED PSYCHOSIS (DUP) IS ASSOCIATED WITH WORSE RESPONSE TO TREATMENT IN ANTIPSYCHOTIC NAïVE FIRST EPISODE PSYCHOSIS
por: Cavalcante, Daniel, et al.
Publicado: (2018)

Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort
por: Santoro, Marcos Leite, et al.
Publicado: (2018)

Hair cortisol in drug-naïve first-episode individuals with psychosis
por: Andrade, Elvis H., et al.
Publicado: (2016)

Schneider’s first-rank symptoms as predictors of remission in antipsychotic-naive first-episode psychosis
por: Malinowski, Fernando R., et al.
Publicado: (2019)

A Study in First-Episode Psychosis Patients: Does Angiotensin I-Converting Enzyme Activity Associated With Genotype Predict Symptom Severity Reductions After Treatment With Atypical Antipsychotic Risperidone?
por: Nani, João V, et al.
Publicado: (2020)

T121. BLUNTED AFFECT EARLY PROGRESSION IN DRUG-NAïVE FIRST EPISODE SCHIZOPHRENIA PATIENTS: 10-WEEK FOLLOW UP
por: Kagan, Simão, et al.
Publicado: (2020)

T97. CANNABIS USE IMPACTS SYMPTOM PRESENTATION IN ANTIPSYCHOTIC NAIVE PATIENTS IN FIRST EPISODE OF PSYCHOSIS (FEP)
por: Coutinho, Luccas, et al.
Publicado: (2018)

Gene expression over the course of schizophrenia: from clinical high-risk for psychosis to chronic stages
por: Ota, Vanessa Kiyomi, et al.
Publicado: (2019)

The role of the CNR1 gene in schizophrenia: a systematic review including unpublished data
por: Gouvêa, Eduardo S., et al.
Publicado: (2017)

Gene expression alterations related to mania and psychosis in peripheral blood of patients with a first episode of psychosis
por: Gouvea, E S, et al.
Publicado: (2016)

S128. CORRELATION OF DURATION OF UNTREATED PSYCHOSIS WITH TREATMENT RESPONSE ON THE SYMPTOM DIMENSIONS OF SCHIZOPHRENIA
por: Elias, Beatriz Yukie, et al.
Publicado: (2018)

F119. MULTILEVEL ANALYSIS IMPROVES THE MODEL FIT OF THE DIMENSIONAL STRUCTURE OF THE PANSS IN PATIENTS WITH SCHIZOPHRENIA
por: Higuchi, Cinthia, et al.
Publicado: (2018)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

Linkage Replication for Chromosomal Region 13q32 in Schizophrenia: Evidence from a Brazilian Pilot Study on Early Onset Schizophrenia Families
por: Gadelha, Ary, et al.
Publicado: (2012)

S174. POLYENVIRONMENTAL AND POLYGENIC RISK SCORES AND THE EMERGENCE OF PSYCHOTIC EXPERIENCES IN CHILDREN AND ADOLESCENTS
por: Belangero, Sintia, et al.
Publicado: (2020)

Gene expression changes associated with trajectories of psychopathology in a longitudinal cohort of children and adolescents
por: Ota, Vanessa Kiyomi, et al.
Publicado: (2020)

Catechol-O-methyltransferase (COMT) polymorphisms modulate working memory in individuals with schizophrenia and healthy controls
por: Matsuzaka, Camila T., et al.
Publicado: (2017)

T176. REDUCED WHITE MATTER ‘CONNECTIVITY’ IN THE SPLENIUM OF THE CORPUS CALLOSUM IN TREATMENT-RESISTANT SCHIZOPHRENIA
por: Assunção-Leme, Idaiane, et al.
Publicado: (2018)

Evaluation of the efficacy of transcranial direct current stimulation in the treatment of cognitive symptomatology in the early stages of psychosis: study protocol for a double-blind randomized controlled trial
por: Rabanea-Souza, Thais, et al.
Publicado: (2019)

Using deep belief network modelling to characterize differences in brain morphometry in schizophrenia
por: Pinaya, Walter H. L., et al.
Publicado: (2016)

Circadian rhythm disturbances and conversion to psychosis in ultra high-risk youth
por: Gonçalves, Bruno, et al.
Publicado: (2016)

Applying polygenic risk scoring for psychiatric disorders to a large family with bipolar disorder and major depressive disorder
por: de Jong, Simone, et al.
Publicado: (2018)

T100. NICOTINE USE IMPACTS NEGATIVE SYMPTOMS SEVERITY IN SCHIZOPHRENIA
por: Oliveira, Hianna, et al.
Publicado: (2018)

Translation and cross-cultural adaptation to Brazilian Portuguese of two brief screening tools for youth at risk of psychosis: the Prodromal Questionnaire (PQ-16) and the PRIME-Screen
por: Aguiar, Ana Paula, et al.
Publicado: (2023)

Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients
por: Birur, Badari, et al.
Publicado: (2020)

Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
por: Louzã, Mário Rodrigues, et al.
Publicado: (2011)

Detecting multiple differentially methylated CpG sites and regions related to dimensional psychopathology in youths
por: Spindola, Leticia M., et al.
Publicado: (2019)

The effect of the severity of obstructive sleep apnea syndrome on telomere length
por: Tempaku, Priscila Farias, et al.
Publicado: (2016)

Diversity matters: opportunities in the study of the genetics of psychotic disorders in low- and middle-income countries in Latin America
por: Fonseca, Lais, et al.
Publicado: (2020)

How challenging is to manage agitated patients?
por: Cavalcante, Daniel A., et al.
Publicado: (2019)

T117. INVESTIGATION OF FORMAL THOUGHT DISORDER AND RESPONSE TO TREATMENT IN SCHIZOPHRENIA
por: Loures Malinowski, Fernando Rocha, et al.
Publicado: (2018)

M200. CLOZAPINE-INDUCED HEPATOTOXICITY: TWO CASE REPORTS
por: Dias, Cintia, et al.
Publicado: (2020)

Risperidone: Acute psychosis secondary to stroke: case report
Publicado: (2020)

PRODH Polymorphisms, Cortical Volumes and Thickness in Schizophrenia
por: Ota, Vanessa K., et al.
Publicado: (2014)

Public school teachers’ perceptions about mental health
por: Soares, Amanda Gonçalves Simões, et al.
Publicado: (2014)

S129. DOES TREATMENT RESISTANT SCHIZOPHRENIA PRESENT A CHARACTERISTIC SYMPTOMATIC SIGNATURE?
por: Bertolucci, Bruno, et al.
Publicado: (2018)

Negative dimension stability across clinical stages and sociodemographic characteristics in schizophrenia
por: Koga, Gabriela, et al.
Publicado: (2022)

Shorter Telomeres Related to Posttraumatic Stress Disorder Re-experiencing Symptoms in Sexually Assaulted Civilian Women
por: Carvalho, Carolina Muniz, et al.
Publicado: (2022)

Clozapine prescription trends in Brazil in the last decade
por: Massuda, Raffael, et al.
Publicado: (2022)

Methamphetamine-Associated Psychosis and Treatment With Haloperidol and Risperidone: A Pilot Study
por: Samiei, Mercede, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_gv9qb7aj88kbi8f3enuthoilp2